Journal article
Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma
K Kazankov, A Rode, K Simonsen, GE Villadsen, A Nicoll, HJ Møller, L Lim, P Angus, I Kronborg, N Arachchi, A Gorelik, D Liew, H Vilstrup, J Frystyk, H Grønbæk
Scandinavian Journal of Clinical and Laboratory Investigation | Published : 2016
Abstract
Background: Tumor associated macrophages are present in hepatocellular carcinoma (HCC) and associated with a poor prognosis. The aim of the present study was to investigate the levels and dynamics of soluble (s)CD163, a specific macrophage activation marker, in patients with HCC. Methods: In a cohort from Australia, we studied 109 HCC patients, 116 patients with chronic liver disease (CLD), and 52 healthy controls. We examined associations between baseline sCD163 and parameters of HCC severity as well as overall and progression-free survival. In a cohort of 42 Danish HCC patients, we measured sCD163 at baseline and 1, 4 and 12 weeks after ablative treatment. Results: In the Australian cohort..
View full abstractGrants
Awarded by Danish Strategic Research Council
Funding Acknowledgements
The NOVO Nordisk Foundation, The Danish Strategic Research Council (10-092797) and "Savvaerksejer Jeppe Juhl og hustru Ovita Juhls mindelegat".